30 Technology expands its clinical team

London, UK, 20 September 2023.

Since the successful divestment of its woundcare business to Convatec Plc, 30 Technology has been actively engaged in expanding its clinical team to drive its lead respiratory assets through multiple ongoing early phase clinical trials.

We are proud to announce our latest new starters – Katie Crevel and Inva Hoti who both hold positions as Associate Directors. Katie will be leading our Non-Cystic Fibrosis Bronchiectasis program and Inva will manage our Tuberculosis clinical program.
They join our Clinical Associates Grace Lee and Mason Ho who all form part of the wider clinical team lead by Dr David Holman who heads 30 Technology’s Clinical Program Management division.

30 TECHNOLOGY is developing nitric oxide-generating technologies for a range of health care applications